Business Wire

Clinical Innovations European Subsidiary Acquires Brenner Medical GmbH

Del

Clinical Innovations, one of the largest medical device companies exclusively focused on labor and delivery and the neonatal intensive care unit, has acquired Brenner Medical GmbH through its wholly owned subsidiary, Clinical Innovations Europe. The acquisition in central Europe broadens Clinical Innovations’ infrastructure in Europe and overall global presence. The purchase will also provide a platform to improve product reach in Germany, the continent’s largest economy.

“Brenner Medical has been a strong partner for many years, and together, our devices allow clinicians to innovate and improve patient outcomes,” said Steve Cash, senior vice president of global sales at Clinical Innovations. “Brenner brings a network of world-class medical device partners and we are eager to integrate those products with our portfolio of complementary products for physicians and nurses.”

Clinical Innovations has consistently expanded its worldwide presence, becoming the market leader in several product categories. The Brenner Medical acquisition builds on the successful creation of Clinical Innovations Europe, which was formed in 2014.

Brenner Medical was founded by owner Angelika Salomon in 1997 and offers innovative products for the fields of obstetrics and gynecology.

“The acquisition of our German distributor allows the company to broaden our commercial reach in a market where we have already enjoyed significant commercial success. We anticipate continued growth opportunities in this strategically important area of the world,” said Ken Reali, president and CEO of Clinical Innovations. “We thank Ms. Salomon for all she has done to support the care of mothers and babies in the German market over the past twenty years,” added Mr. Reali.

“We are pleased to see Clinical Innovations continue to take steps to enhance its commercial platform, and the Brenner Medical acquisition is a significant step forward,” said Mike Lynch, operating partner at Pritzker Group Private Capital.

Clinical Innovations is a member of the Pritzker Group’s family of companies.

About Clinical Innovations

Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and the neonatal intensive care unit. The company is already a market leader in several categories with products such as the Koala® Intrauterine Pressure Catheter; Kiwi® Vacuum-Assisted Delivery System; ROM Plus® Rupture of Membranes Test; traxi® Panniculus Retractor; ClearView Uterine Manipulator; babyLance Safety Heelstick; and the recently added ebb Complete Tamponade System. Clinical Innovations is expanding its global presence while developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Clinical Innovations is a Pritzker Group company. For more information, visit clinicalinnovations.com.

About Pritzker Group

Pritzker Group, founded by Tony and J.B. Pritzker, has three principal investment teams: Private Capital, which acquires and operates leading North America-based companies; Venture Capital, which provides early-stage and growth venture funding to technology companies throughout the United States; and Asset Management, which partners with top-performing investment managers across global public markets.

Pritzker Group Private Capital acquires North America-based middle-market companies with leading positions in the manufactured products, services and health care sectors. The firm’s permanent, proprietary capital base allows for efficient decision making, broad flexibility with transaction structure and investment horizon, and alignment with management teams focused on creating long-term value. Pritzker Group brings significant resources, expertise and credibility in building businesses and is an ideal partner for entrepreneur- and family-owned companies. For more information, visit pritzkergroup.com.

Contact information

Aileron Communications
Dave Lundy, 312.629.9400
dlundy@aileroninc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

CyberOptics Demonstrates New MRS-Enabled AOI, SPI and CMM Solutions at productronica Germany17.10.2017 13:00Pressemelding

CyberOptics® Corporation (NASDAQ:CYBE), a leading global developer and manufacturer of high-precision 3D sensing technology solutions, will demonstrate the SQ3000™-DD 3D Automated Optical Inspection (AOI) system with the new Ultra-High Resolution Multiple-Reflection Suppression (MRS) Sensors in Hall A4, Stand 239 at productronica 2017, scheduled to take place Nov. 14 – 17, 2017 at the Messe München in Germany. The company also will unveil the new SE3000™ 3D SPI and SQ3000™ 3D CMM, both powered by MRS technology. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005732/en/ CyberOptics SQ3000-DD AOI System (Photo: Business Wire) The new SQ3000-DD 3D AOI dual lane, dual sensor system maximizes flexibility catering to varying PCB widths. This unique design provides the ability to inspect

Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics17.10.2017 12:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team. Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He has been instrumental in expanding Gilead’s oncology program with the recent acquisition of Kite Pharma, establishing the company as a leader in the field of cellular therapy. He has also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure. Prior to joining Gilead, Dr. Riva served as Head, Global Oncology Development at Novartis, where he oversaw the development and worldwide regulatory approval of multi

First Eagle Investment Management Agrees to Acquire NewStar Financial17.10.2017 11:00Pressemelding

First Eagle Investment Management (“First Eagle”) and NewStar Financial Inc. (Nasdaq:NEWS) ("NewStar”) announced today that they have entered into a definitive agreement for First Eagle to acquire NewStar, an established lender and investment manager specializing in direct lending to middle-market companies and management of broadly syndicated loans. NewStar stockholders are expected to receive total consideration estimated at $12.32 to $12.44 per share, which represents a premium of 10.4% to 11.5% over NewStar's 3-month volume weighted average price of $11.16 as of October 16, 2017, the last trading day before the transaction announcement. The contingent value rights entitle the holders to certain tax refunds generated by the transaction, the amount of which will vary depending upon, among other things, whether the transaction closes in 2017 or 2018. This press release features multimedia.

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy17.10.2017 11:00Pressemelding

Eos Biosciences, Inc., a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for Eos-001, the company’s HER3-targeted Eosome with doxorubicin payload. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “This is a very exciting time for Eos Biosciences. In addition to expanding and solidifying our patent portfolio, we are making very significant progress on the pre-clinical development and scale-up manufacturing of our products.” Dr. Haffar continued, “We are also implementing a strategic expansion of our product pipeline into immuno-oncology, and the application of Eosomes to other high impact di

1 Million MOTION CODE™ Online Transactions With Société Générale17.10.2017 10:07Pressemelding

IDEMIA, the global leader in trusted identities for an increasingly digital world, today announced the milestone of 1 million MOTION CODE TM online transactions with Société Générale. Société Générale was one of the first banks worldwide to launch MOTION CODE™, the next-generation card integrating a dynamic security code by IDEMIA (formerly known as OT-Morpho). This solution consists in replacing the 3 digits of the cryptogram printed on the back of the card with a small screen displaying a new “dynamic” code every hour. Thus, in case of piracy of the bank card’s data, the 3 digits of the cryptogram quickly become obsolete, preventing fraudsters from reusing data, especially on e-commerce sites. After successful testing among more than 500 people in 2016, Société Générale started offering MOTION CODE™ to all their French customers early 2017. In les

Mobile Ticket Option Launches for Tampa Bay CityPASS17.10.2017 09:00Pressemelding

City Pass, Inc., the company that specializes in packaging discounted admission to the most iconic attractions in 12 North American destinations, recently launched a mobile ticket option for its Tampa Bay CityPASS® program. Since 1997, CityPASS products have been designed to make travel easier and less expensive. And while the Tampa Bay CityPASS program will continue to excel at the latter—saving visitors 51 percent off combined admission to the included attractions—the new mobile ticket option dramatically enhances the convenience factor. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005538/en/ Busch Gardens Tampa Bay (Photo: SeaWorld Parks & Entertainment, Inc.) “We’re always looking for ways to improve the customer experience and make travel more convenient,” said CityPASS President a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom